Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Patients with head and neck cancer who cannot receive cisplatin now have new hope.

2.

The Boom in ADHD Coaching Has Few Rules

3.

Q&A: Why adolescents and young adults with cancer are falling behind

4.

Adaptive SABR-Used Hypofractionated Chemoradiation Showed Good Results in NSCLC.

5.

Making informed decisions and managing regret after prostate cancer treatment


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot